Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM PHENYLACETATE AND SODIUM BENZOATE vs PHEBURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.
Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.
Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), argininosuccinic acid synthetase (AS), argininosuccinic acid lyase (AL), or arginase (ARG). Also used for maintenance therapy in chronic management of UCDs.
Adjunct therapy for nitrogen removal in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase,Off-label: Management of hyperammonemia in other conditions
Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.
Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.
The terminal elimination half-life of phenylacetate is approximately 0.5-0.8 hours; however, its active conjugate phenylacetylglutamine has a half-life of about 1.2-1.5 hours. For benzoate, the half-life is approximately 0.5-1 hour. In the context of hyperammonemia treatment, the clinical effect correlates with the rapid formation of conjugates, and the half-life reflects quick clearance. In neonates or patients with renal impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged (up to 4-6 hours), necessitating dose adjustment.
Sodium phenylacetate is metabolized via conjugation with glutamine to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine to form hippurate. Both metabolites are rapidly excreted by the kidneys.
Primarily hepatic and renal; hydrolyzed by esterases to phenylacetate; phenylacetate then conjugated with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Sodium phenylacetate and sodium benzoate are primarily excreted renally. Phenylacetate is conjugated with glutamine to form phenylacetylglutamine, which is rapidly eliminated in urine. Benzoate is conjugated with glycine to form hippurate, also renally eliminated. Approximately 80-100% of the administered dose is recovered in urine as conjugates and minor metabolites. Fecal excretion is negligible (<5%).
Primarily renal excretion. Approximately 50-80% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Phenylacetate and benzoate are highly protein bound, primarily to albumin. Protein binding is approximately 80-90% for phenylacetate and 75-85% for benzoate. Binding may be saturable at high concentrations.
Approximately 10-20% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
The apparent volume of distribution for both drugs is small, approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. This is consistent with their high protein binding and confinement to the vascular and interstitial spaces.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. Not extensively distributed into tissues.
Oral bioavailability is high, approximately 80-90% for both components, as they are well absorbed. However, for acute hyperammonemia, intravenous administration is preferred to ensure rapid and complete delivery.
Oral bioavailability is approximately 80-100% after administration of the sodium phenylbutyrate prodrug. PHEBURANE itself is a prodrug; bioavailability refers to conversion to phenylacetate and then to phenylacetylglutamine.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-50: reduce dose by 50% and monitor ammonia levels.
Contraindicated in patients with GFR < 50 m L/min/1.73 m² due to risk of hyperammonemia.
No specific adjustment; use with caution in severe hepatic impairment due to potential for increased ammonia.
No specific adjustment recommended for Child-Pugh A or B. Use with caution in severe hepatic impairment (Child-Pugh C) due to limited data.
Same weight-based dosing as adults: 5.5 g/m² IV loading then 5.5 g/m²/24h continuous infusion.
Neonates and children: 4.5 to 5.9 grams/m²/day orally in 2 to 4 divided doses. Doses up to 12.5 grams/day have been used.
No specific adjustment; monitor renal function and consider reduced dosing based on creatinine clearance.
No specific adjustments recommended; use with caution due to age-related renal decline. Monitor renal function and ammonia levels.
WARNING: Contains sodium (approximately 30.2 mg/m L from sodium phenylacetate and sodium benzoate). Use caution in patients with congestive heart failure, severe renal insufficiency, or conditions with sodium retention. Additionally, neurotoxicity has been associated with phenylacetate accumulation; monitor plasma levels.
None
Monitor ammonia levels, electrolytes, and neurological status. Risk of hypernatremia due to sodium content. Phenylacetate may cause neurotoxicity (tremors, agitation, coma) at high concentrations. Use with caution in patients with hepatic or renal impairment. Not recommended for patients with known hypersensitivity to phenylacetate or benzoate. Extravasation risk: avoid extravasation; if occurs, treat locally.
May cause fluid retention and electrolyte abnormalities (e.g., hypernatremia, hypokalemia) due to sodium content,Pancreatitis has been reported,Neurotoxicity with high plasma phenylacetate levels (e.g., somnolence, confusion, seizures),May impair platelet function; caution in bleeding disorders or surgery,Monitor ammonia levels, serum electrolytes, liver function, and complete blood counts regularly
Known hypersensitivity to sodium phenylacetate, sodium benzoate, or any component of the formulation; pre-existing severe hypernatremia (serum sodium >150 m Eq/L); neonates with hyperbilirubinemia (risk of kernicterus due to benzoate displacing bilirubin from albumin).
Hypersensitivity to sodium phenylbutyrate or any component of the formulation,Patients in whom adequate nitrogen removal cannot be achieved or who are not suitable for alternative therapy (e.g., hemodialysis)
Administer with food or enteral feeding to reduce gastrointestinal irritation. Avoid high-protein meals during treatment as they may increase ammonia production. No specific food-drug interactions; restrict dietary protein as part of urea cycle disorder management (typically 0.5-2 g/kg/day).
Avoid high-protein foods as they increase ammonia production. Take with meals to improve tolerability. No known significant food-drug interactions.
FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal and visceral malformations) when administered during organogenesis. Human data are insufficient to determine fetal risk. In the first trimester, potential for teratogenicity exists; use only if maternal benefit outweighs risk. Second and third trimester exposure may be associated with neonatal metabolic alkalosis, hypernatremia, and potential for kernicterus due to displacement of bilirubin from albumin. Avoid use during labor and delivery due to risk of neonatal hyperbilirubinemia.
Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First trimester: Potential for teratogenicity based on animal data. Second and third trimesters: May cause fetal growth restriction and neurotoxicity due to ammonia-lowering effects. Use only if benefit outweighs risk.
Excretion into human breast milk is unknown. The molecular weight of both sodium phenylacetate and sodium benzoate suggests potential for transfer into breast milk. The Milk-to-Plasma ratio is not established. Because of potential for serious adverse reactions in nursing infants (e.g., metabolic acidosis, neurotoxicity), breastfeeding is not recommended during therapy. Alternative feeding methods should be considered.
It is unknown if sodium phenylbutyrate or its metabolites are excreted in human milk. The M/P ratio has not been established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
Pregnancy-induced hemodilution and increased renal clearance may require dose adjustments to maintain therapeutic ammonia levels. Monitor serum ammonia closely; consider starting at lower doses and titrating based on response. Due to increased plasma volume, distribution volume changes, and enhanced renal excretion, dose adjustments upward may be necessary. However, avoid excessive dosing to prevent maternal metabolic alkalosis or hypernatremia. Individualize therapy based on frequent ammonia monitoring, with consideration of gestational age. Postpartum, dose may need to be reduced as renal function normalizes.
Pregnancy may alter pharmacokinetics of sodium phenylbutyrate due to increased plasma volume, renal clearance, and hepatic metabolism. Although specific dose adjustment recommendations are lacking, consider monitoring ammonia levels closely and titrating dose to maintain therapeutic ammonia control. Dose may need to be increased in late pregnancy and postpartum. Start at the lowest effective dose.
Administer intravenously via central line due to hypertonicity (p H 9-9.5). Monitor serum ammonia, potassium, and bicarbonate closely; hypokalemia and metabolic alkalosis are common. Use with caution in renal impairment (dose adjust for GFR <30 m L/min). Discontinue if hypernatremia or volume overload occurs. Caloric content: 2.5 kcal/m L from phenylacetate and benzoate.
PHEBURANE (sodium phenylbutyrate) is used as adjunctive therapy for urea cycle disorders. Monitor plasma ammonia, arginine, and glutamine levels. Avoid in patients with severe hepatic impairment. Discontinue if hyperammonemic encephalopathy occurs.
This medication is used to remove excess ammonia from your blood due to a urea cycle disorder.,It is given through a central intravenous line; report any pain, redness, or swelling at the infusion site.,You may experience nausea, vomiting, or headache; notify your healthcare provider if severe.,Regular blood tests are necessary to monitor your ammonia levels and electrolytes.,Avoid taking other medications without consulting your doctor, as they may affect ammonia levels.
Take with food or milk to reduce gastrointestinal irritation.,Do not crush or chew tablets; swallow whole.,Report any signs of hyperammonemia (e.g., lethargy, vomiting, confusion) immediately.,Maintain a low-protein diet as prescribed.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM PHENYLACETATE AND SODIUM BENZOATE vs PHEBURANE, answered by our medical review team.
SODIUM PHENYLACETATE AND SODIUM BENZOATE is a Ammonia Detoxicant that works by Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.. PHEBURANE is a Ammonia Detoxicant that works by Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM PHENYLACETATE AND SODIUM BENZOATE and PHEBURANE depend on the specific clinical indication. These are both Ammonia Detoxicant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM PHENYLACETATE AND SODIUM BENZOATE is: Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.. The standard adult dose of PHEBURANE is: Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM PHENYLACETATE AND SODIUM BENZOATE and PHEBURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM PHENYLACETATE AND SODIUM BENZOATE is classified as Category C. FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal an. PHEBURANE is classified as Category C. Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.